Steven Falcone
COO, Elevatebio
Steven Falcone is listed as COO, Elevatebio. Steven is scheduled to speak at Advanced Therapies Week 2027 on 20 January 2027.
Compiled from published conference agendas; not yet confirmed by Steven. Is this you? Claim this profile.
About
Steve Falcone is the Chief Operating Officer at ElevateBio. Steve brings more than 30 years of operations, quality, and compliance leadership across global biopharmaceutical manufacturing. Prior to joining ElevateBio, Steve served as Vice President of Quality Complaints, Audit and Inspections, and Quality Intelligence at Novo Nordisk, where he set strategic direction for the company’s global audit, inspection, and complaint programs. His previous roles include Chief Quality Officer for Brammer Bio (acquired by Thermo Fisher) and VP and Senior Director at Thermo Fisher where he transformed their inspection readiness and external engagement programs, as well as supported creation of new business services for advanced therapies including plasmid, mRNA, cell therapy and regulatory affairs offerings. Prior roles include VP of Quality at Sanofi Genzyme and various quality and operational positions at Amgen, Solstice Neurosciences and Bayer.
Upcoming
Advanced Therapies Week 2027 19 January 2027 – 21 January 2027
- Session 6: Cell therapy product characterization and QC Speaker · 20 January 2027
Spoke alongside
People who have shared a session with Steven at events on B2DB.
- Alejandra Gutierrez Guerrero Product Manager, Cell Therapy Biomaterial · Grifols Bio Supplies 1 shared session
- Damian Marshall VP - Analytical Development · Resolution Therapeutics 1 shared session
- Erin Cross Vice President of Development · KROMATID 1 shared session
- Nolan Polson Vice President, Quality Assurance & Product Quality · Iovance Biotherapeutics, Inc. 1 shared session
- Therese Choquette CTO · Tigen Pharma 1 shared session